Just last month, Bioverativ (NASDAQ:$BIVV) and Invicro signed a strategic collaboration in developing advanced imaging technologies for the diagnosis and treatment of joint diseases for patients with hemophilia.

In June 2017, Bioverativ acquired True North Therapeutics, adding TNT009, an investigational moncional antibody for cold agglutinin disease to Bioveratic’s pipeline.

Around 33% of analysts tracking Bioverativ in August 2017 recommended a “buy” option. On September 4th, 2017, Bioverativ had a mean 12-month target price of $64.44, representing a 15.2% return on investment.

In 1H17, Bioverativ saw revenues of around $505.08 million, representing a 36% growth on year over year basis.

In 2Q17, Bioverativ’s Eloctate saw revenues of around $174 million; growing 59.5% in Japan, 36.2% in the US, and 129.1% in Canada, year over year.

Let’s take a look at Bioverativ’s competition 

Around 80% of analysts tracking Alexion Pharmaceuticals (NASDAQ:$ALXN) recommended a buy. On September 4th, Alexion had a mean 12-month target price of $158.95, representing a 10.3% return over the next 12 months.

Around 100% of analysts tracking Neurocrine Biosciences (NASDAQ:$NBIX) recommended some form of a buy. NBIX had a mean 12-month target price of $73.33, representing a 28.6% return over the next 12 months.

Around 80% of analysts tracking Vertex Pharmaceuticals (NASDAQ:$VRTX) recommended some form of a buy. Vertex had a mean 12-month target of $179.09, representing a 9.8% return over the next 12 months.

Bioverativ’s new drug Eloctate will undeniably be a significant long-term growth driver for the company, which is on track to start a phase-1/2a clinical trial with BIVV001 in 2H17.

Featured Image: twitter